Circle Pharma is a biotechnology company which offers macrocycle therapeutics to patients with diseases and cancers. Circle Pharma’s proprietary MXMO™ platform is designed to target intracellular protein-protein interactions (PPIs), combining drug design with synthetic chemistry advancements to create drug candidates that are intended to be cell-permeable and orally bioavailable for oncology treatments. This company was founded by Matthew Jacobson Ph.D and Scott Lokey Ph.D in 2012 and is headquartered in South San Francisco, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/03/2024 | Series D | $90MM | $xx.xx | $286.88MM | The Column Group, Nextech Invest, Euclidean Capital | |
Price per Share
$xx.xx
Shares Outstanding
143,380,596
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
The Column Group, Nextech Invest, Euclidean Capital
|
||||||
06/16/2021 | Series C | $66.3MM | $xx.xx | $257.55MM | The Column Group, Nextech Invest, Pandect Bioventures, ShangPharma Innovation, LifeForce Capital, Berkeley Catalyst Fund, Euclidean Capital, Pavillion Capital, Hartford HealthCare Endowment, Eli Lilly and Company | |
Price per Share
$xx.xx
Shares Outstanding
78,005,871
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
The Column Group, Nextech Invest, Pandect Bioventures, ShangPharma Innovation, LifeForce Capital, Berkeley Catalyst Fund, Euclidean Capital, Pavillion Capital, Hartford HealthCare Endowment, Eli Lilly and Company
|
||||||
03/17/2020 | Series B | $45MM | $xx.xx | $92.99MM | The Column Group, Nextech Invest, ShangPharma Innovation, LifeForce Capital, Berkeley Catalyst Fund, Pandect Bioventures | |
Price per Share
$xx.xx
Shares Outstanding
104,651,160
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
The Column Group, Nextech Invest, ShangPharma Innovation, LifeForce Capital, Berkeley Catalyst Fund, Pandect Bioventures
|
||||||
04/25/2017 | Series A | $2.5MM | $xx.xx | $15.56MM | Mission Bay Capital, Pfizer, ShangPharma Innovation, WI Harper Group, Elements Partners, Whitesun Healthcare Ventures, LifeForce Capital, Berkeley Catalyst Fund | |
Price per Share
$xx.xx
Shares Outstanding
5,108,742
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Mission Bay Capital, Pfizer, ShangPharma Innovation, WI Harper Group, Elements Partners, Whitesun Healthcare Ventures, LifeForce Capital, Berkeley Catalyst Fund
|
||||||
12/21/2016 | Series A-1 | $4.5MM | $xx.xx | $12.86MM | Mission Bay Capital, Pfizer, ShangPharma Innovation | |
Price per Share
$xx.xx
Shares Outstanding
9,183,673
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Mission Bay Capital, Pfizer, ShangPharma Innovation
|